Chronic Δ9-tetrahydrocannabinol exposure induces a sensitization of dopamine D2/3 receptors in the mesoaccumbens and nigrostriatal systems

Neuropsychopharmacology

Volumn 37, Issue 11, 2012, Pages 2355-2367

  Ginovart, Nathalie ^a,b   Tournier, Benjamin B ^a,b   Moulin Sallanon, Marcelle ^b,c   Steimer, Thierry ^b   Ibanez, Vicente ^b   Millet, Philippe ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c French Clinical Research Infrastructure Network   (France)

Author keywords

9 tetrahydrocannabinol; addiction; CB1 receptors; D2 receptors; D3 receptors; dopamine

Indexed keywords

AMPHETAMINE; CANNABINOID 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DRONABINOL; MESSENGER RNA; QUINPIROLE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; DRUG EXPOSURE; GENE EXPRESSION; GLOBUS PALLIDUS; IN VIVO CULTURE; IN VIVO STUDY; LIMBIC SYSTEM; LOCOMOTION; MALE; MESENCEPHALON; NEUROTRANSMISSION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHOMOTOR ACTIVITY; PUTAMEN; RAT; RECEPTOR BINDING; SENSITIZATION; SIGNAL TRANSDUCTION; UPREGULATION;

AMPHETAMINE; ANALYSIS OF VARIANCE; ANIMALS; BASAL GANGLIA; BENZAMIDES; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FLUORODEOXYGLUCOSE F18; GENE EXPRESSION REGULATION; LOCOMOTION; MALE; NUCLEUS ACCUMBENS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; PSYCHOTROPIC DRUGS; QUINPIROLE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RNA, MESSENGER; TETRAHYDROCANNABINOL; TRITIUM; VITAMIN K 1;

EID: 84866430898     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.91     Document Type: Article

References (75)

1. Aghajanian GK, Bunney BS (1977). Dopamine 'autoreceptors': pharmacological characterization by microiontophoretic single cell recording studies. Naunyn Schmiedebergs Arch Pharmacol 297: 1-7. (Pubitemid 8063109)
2. Arseneault L, Cannon M, Witton J, Murray RM (2004). Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 184: 110-117. (Pubitemid 38186851)
3. Beltramo M, de Fonseca FR, Navarro M, Calignano A, Gorriti MA, Grammatikopoulos G et al (2000). Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor. J Neurosci 20: 3401-3407. (Pubitemid 30263155)
4. Berrendero F, Sepe N, Ramos JA, Di Marzo V, Fernandez-Ruiz JJ (1999). Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period. Synapse 33: 181-191. (Pubitemid 29372845)
5. Breese GR, Duncan GE, Napier TC, Bondy SC, Iorio LC, Mueller RA (1987). 6-Hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1-and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding. J Pharmacol Exp Ther 240: 167-176. (Pubitemid 17235435)
6. Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Vogt LJ, Sim-Selley LJ (1999). Chronic delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. J Neurochem 73: 2447-2459.
7. Cadoni C, Valentini V, Di Chiara G (2008). Behavioral sensitization to delta 9-tetrahydrocannabinol and cross-sensitization with morphine: differential changes in accumbal shell and core dopamine transmission. J Neurochem 106: 1586-1593.
8. Chen JP, Paredes W, Li J, Smith D, Lowinson J, Gardner EL (1990). Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology (Berl) 102: 156-162. (Pubitemid 20264653)
9. Dalley JW, Fryer TD, Brichard L, Robinson ES, Theobald DE, Laane K et al (2007). Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science 315: 1267-1270. (Pubitemid 46364262)
10. Dalton VS, Zavitsanou K (2010). Differential treatment regimenrelated effects of cannabinoids on D1 and D2 receptors in adolescent and adult rat brain. J Chem Neuroanat 40: 272-280.
11. Davis KL, Kahn RS, Ko G, Davidson M (1991). Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148: 1474-1486.
12. Diana M, Melis M, Muntoni AL, Gessa GL (1998). Mesolimbic dopaminergic decline after cannabinoid withdrawal. Proc Natl Acad Sci USA 95: 10269-10273. (Pubitemid 28415330)
13. Eilam D, Szechtman H (1989). Biphasic effect of D-2 agonist quinpirole on locomotion and movements. Eur J Pharmacol 161: 151-157. (Pubitemid 19080497)
14. Ferraro L, Frankowska M, Marcellino D, Zaniewska M, Beggiato S, Filip M et al (2012). A novel mechanism of cocaine to enhance dopamine D(2)-like receptor mediated neurochemical and behavioral effects. An in vivo and in vitro study. Neuropsychopharmacology; e-pub ahead of print 28 March 2012. doi: 10.1038/npp.2012.33.
15. Fitzgerald ML, Shobin E, Pickel VM (2012). Cannabinoid modulation of the dopaminergic circuitry: Implications for limbic and striatal output. Prog Neuropsychopharmacol Biol Psychiatry; e-pub ahead of print 11 January 2012. doi: 10.1016/j.pnpbp.2011.12.004.
16. Freedman SB, Patel S, Marwood R, Emms F, Seabrook GR, Knowles MR et al (1994). Expression and pharmacological characterization of the human D3 dopamine receptor. J Pharmacol Exp Ther 268: 417-426. (Pubitemid 24039117)
17. French ED, Dillon K, Wu X (1997). Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport 8: 649-652. (Pubitemid 27128210)
18. Gessa GL, Melis M, Muntoni AL, Diana M (1998). Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. Eur J Pharmacol 341: 39-44. (Pubitemid 28041196)
19. Ghozland S, Matthes HW, Simonin F, Filliol D, Kieffer BL, Maldonado R (2002). Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. J Neurosci 22: 1146-1154. (Pubitemid 34141794)
20. Ginovart N, Galineau L, Willeit M, Mizrahi R, Bloomfield PM, Seeman P et al (2006). Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. J Neurochem 97: 1089-1103.
21. Giuffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, Piomelli D (1999). Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2: 358-363. (Pubitemid 30491279)
22. Green AI, Burgess ES, Dawson R, Zimmet SV, Strous RD (2003). Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophr Res 60: 81-85. (Pubitemid 36015790)
23. Houchi H, Babovic D, Pierrefiche O, Ledent C, Daoust M, Naassila M (2005). CB1 receptor knockout mice display reduced ethanolinduced conditioned place preference and increased striatal dopamine D2 receptors. Neuropsychopharmacology 30: 339-349. (Pubitemid 40129485)
24. Johns A (2001). Psychiatric effects of cannabis. Br J Psychiatry 178: 116-122. (Pubitemid 32158073)
25. Karnovsky MJ, Roots L (1964). A 'direct-coloring' thiocholine method for cholinesterases. J Histochem Cytochem 12: 219-221.
26. Kearn CS, Blake-Palmer K, Daniel E, Mackie K, Glass M (2005). Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Mol Pharmacol 67: 1697-1704. (Pubitemid 40594170)
27. Kling-Petersen T, Ljung E, Svensson K (1995). Effects on locomotor activity after local application of D3 preferring compounds in discrete areas of the rat brain. J Neural Transm Gen Sect 102: 209-220. (Pubitemid 26010728)
28. Kreuz DS, Axelrod J (1973). Delta-9-tetrahydrocannabinol: localization in body fat. Science 179: 391-393.
29. Large M, Sharma S, Compton MT, Slade T, Nielssen O (2011). Cannabis use and earlier onset of psychosis: A systematic meta-analysis. Arch Gen Psychiatry 68: 555-561.
30. Laviolette SR, Grace AA (2006). The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction. Cell Mol Life Sci 63: 1597-1613. (Pubitemid 44252174)
31. Le Foll B, Diaz J, Sokoloff P (2003). Increased dopamine D3 receptor expression accompanying behavioral sensitization to nicotine in rats. Synapse 47: 176-183. (Pubitemid 36056831)
32. Le Foll B, Frances H, Diaz J, Schwartz JC, Sokoloff P (2002). Role of the dopamine D3 receptor in reactivity to cocaine-associated cues in mice. Eur J Neurosci 15: 2016-2026. (Pubitemid 35471890)
33. Le Foll B, Wiggins M, Goldberg SR (2006). Nicotine pre-exposure does not potentiate the locomotor or rewarding effects of Delta-9-tetrahydrocannabinol in rats. Behav Pharmacol 17: 195-199.
34. Lepore M, Liu X, Savage V, Matalon D, Gardner EL (1996). Genetic differences in delta 9-tetrahydrocannabinol-induced facilitation of brain stimulation reward as measured by a rate-frequency curve-shift electrical brain stimulation paradigm in three different rat strains. Life Sci 58: PL365-PL372. (Pubitemid 126334928)
35. Liem-Moolenaar M, te Beek ET, de Kam ML, Franson KL, Kahn RS, Hijman R et al (2010). Central nervous system effects of haloperidol on THC in healthy male volunteers. J Psychopharmacol 24: 1697-1708.
36. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL (1996). Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 16: 834-840. (Pubitemid 26292051)
37. Lopez-Moreno JA, Scherma M, Rodriguez de Fonseca F, Gonzalez-Cuevas G, Fratta W, Navarro M (2008). Changed accumbal responsiveness to alcohol in rats pre-treated with nicotine or the cannabinoid receptor agonist WIN 55,212-2. Neurosci Lett 433: 1-5.
38. Lupica CR, Riegel AC, Hoffman AF (2004). Marijuana and cannabinoid regulation of brain reward circuits. Br J Pharmacol 143: 227-234. (Pubitemid 39315142)
39. Mailleux P, Vanderhaeghen JJ (1992). Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 48: 655-668.
40. Mailleux P, Vanderhaeghen JJ (1993). Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study. J Neurochem 61: 1705-1712. (Pubitemid 23317193)
41. Marcellino D, Carriba P, Filip M, Borgkvist A, Frankowska M, Bellido I et al (2008a). Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis. Neuropharmacology 54: 815-823.
42. Marcellino D, Ferre S, Casado V, Cortes A, Le Foll B, Mazzola C et al (2008b). Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum. J Biol Chem 283: 26016-26025.
43. Marcellino D, Navarro G, Sahlholm K, Nilsson J, Agnati LF, Canela EI et al (2010). Cocaine produces D2R-mediated conformational changes in the adenosine A(2A)R-dopamine D2R heteromer. Biochem Biophys Res Commun 394: 988-992.
44. Matyas F, Urban GM, Watanabe M, Mackie K, Zimmer A, Freund TF et al (2008). Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area. Neuropharmacology 54: 95-107. (Pubitemid 350299400)
45. Matyas F, Yanovsky Y, Mackie K, Kelsch W, Misgeld U, Freund TF (2006). Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia. Neuroscience 137: 337-361. (Pubitemid 43031500)
46. McKinney DL, Cassidy MP, Collier LM, Martin BR, Wiley JL, Selley DE et al (2008). Dose-related differences in the regional pattern of cannabinoid receptor adaptation and in vivo tolerance development to delta9- tetrahydrocannabinol. J Pharmacol Exp Ther 324: 664-673. (Pubitemid 351185869)
47. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M et al (2007). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370: 319-328. (Pubitemid 47094993)
48. Moranta D, Esteban S, Garcia-Sevilla JA (2009). Chronic treatment and withdrawal of the cannabinoid agonist WIN 55,212-2 modulate the sensitivity of presynaptic receptors involved in the regulation of monoamine syntheses in rat brain. Naunyn Schmiedebergs Arch Pharmacol 379: 61-72.
49. Moreno M, Lopez-Moreno JA, Rodriguez de Fonseca F, Navarro M (2005). Behavioural effects of quinpirole following withdrawal of chronic treatment with the CB1 agonist, HU-210, in rats. Behav Pharmacol 16: 441-446. (Pubitemid 41404816)
50. Motta A, Damiani C, Del Guerra A, Di Domenico G, Zavattini G (2002). Use of a fast EM algorithm for 3D image reconstruction with the YAP-PET tomograph. Comput Med Imaging Graph 26: 293-302. (Pubitemid 36151584)
51. Mukherjee J, Yang ZY, Brown T, Lew R, Wernick M, Ouyang X et al (1999). Preliminary assessment of extrastriatal dopamine D-2 receptor binding in the rodent and nonhuman primate brains using the high affinity radioligand, 18F-fallypride. Nucl Med Biol 26: 519-527. (Pubitemid 29378486)
52. Paxinos G, Watson C (1998). The Rat Brain in Stereotaxic Coordinates. Academic Press: San Diego. Pfaffl MW (2001). A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
53. Pickel VM, Chan J, Kearn CS, Mackie K (2006). Targeting dopamine D2 and cannabinoid-1 (CB1) receptors in rat nucleus accumbens. J Comp Neurol 495: 299-313. (Pubitemid 43271474)
54. Rabiner EA, Slifstein M, Nobrega J, Plisson C, Huiban M, Raymond R et al (2009). In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: Studies in non-human primates and transgenic mice. Synapse 63: 782-793.
55. Robinson TE, Berridge KC (2008). Review. The incentive sensitization theory of addiction: some current issues. Philos Trans R Soc Lond B Biol Sci 363: 3137-3146.
56. Rodriguez de Fonseca F, Gorriti MA, Fernandez-Ruiz JJ, Palomo T, Ramos JA (1994). Downregulation of rat brain cannabinoid binding sites after chronic delta 9-tetrahydrocannabinol treatment. Pharmacol Biochem Behav 47: 33-40.
57. Romero J, Berrendero F, Manzanares J, Perez A, Corchero J, Fuentes JA et al (1998). Time-course of the cannabinoid receptor down-regulation in the adult rat brain caused by repeated exposure to delta9-tetrahydrocannabinol. Synapse 30: 298-308. (Pubitemid 28447177)
58. Rominger A, Wagner E, Mille E, Boning G, Esmaeilzadeh M, Wangler B et al (2010). Endogenous competition against binding of [(18)F]DMFP and [(18)F]fallypride to dopamine D(2/3) receptors in brain of living mouse. Synapse 64: 313-322.
59. Rossetti ZL, Hmaidan Y, Gessa GL (1992). Marked inhibition of mesolimbic dopamine release: a common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats. Eur J Pharmacol 221: 227-234.
60. Safont G, Corripio I, Escarti MJ, Portella MJ, Perez V, Ferrer M et al (2011). Cannabis use and striatal D2 receptor density in untreated first-episode psychosis: an in vivo SPECT study. Schizophr Res 129: 169-171.
61. Schweinhardt P, Fransson P, Olson L, Spenger C, Andersson JL (2003). A template for spatial normalisation of MR images of the rat brain. J Neurosci Methods 129: 105-113. (Pubitemid 37162881)
62. Sevy S, Smith GS, Ma Y, Dhawan V, Chaly T, Kingsley PB et al (2008). Cerebral glucose metabolism and D2/D3 receptor availability in young adults with cannabis dependence measured with positron emission tomography. Psychopharmacology (Berl) 197: 549-556.
63. Sim-Selley LJ (2003). Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit Rev Neurobiol 15: 91-119. (Pubitemid 38160440)
64. Spanagel R, Almeida OF, Bartl C, Shippenberg TS (1994). Endogenous kappa-opioid systems in opiate withdrawal: role in aversion and accompanying changes in mesolimbic dopamine release. Psychopharmacology (Berl) 115: 121-127. (Pubitemid 24207771)
65. Staley JK, Mash DC (1996). Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J Neurosci 16: 6100-6106. (Pubitemid 26313985)
66. Stokes PR, Egerton A, Watson B, Reid A, Lappin J, Howes OD et al (2012). History of cannabis use is not associated with alterations in striatal dopamine D2/D3 receptor availability. J Psychopharmacol 26: 144-149.
67. Tanda G, Loddo P, Di Chiara G (1999). Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol. Eur J Pharmacol 376: 23-26. (Pubitemid 29320166)
68. Tanda G, Pontieri FE, Di Chiara G (1997). Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 276: 2048-2050. (Pubitemid 27443611)
69. Taylor DA, Sitaram BR, Elliot-Baker S (1988). Effect of 9-tetrahydrocannabinol on release of dopamine in the corpus striatum of the rat. In: Chesher G, Consroe P, Musty R (eds). Marijuana: An International Research Report. Australian Govt. Publ. Service: Canberra. pp 405-408.
70. Thanos PK, Gopez V, Delis F, Michaelides M, Grandy DK, Wang GJ et al (2011). Upregulation of cannabinoid type 1 receptors in dopamine D2 receptor knockout mice is reversed by chronic forced ethanol consumption. Alcohol Clin Exp Res 35: 19-27.
71. Valjent E, Maldonado R (2000). A behavioural model to reveal place preference to delta 9-tetrahydrocannabinol in mice. Psychopharmacology (Berl) 147: 436-438. (Pubitemid 30048492)
72. van Nimwegen LJ, de Haan L, van Beveren NJ, van der Helm M, van den Brink W, Linszen D (2008). Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial. Can J Psychiatry 53: 400-405. (Pubitemid 351878642)
73. Westerink BH, Kwint HF, deVries JB (1996). The pharmacology of mesolimbic dopamine neurons: a dual-probe microdialysis study in the ventral tegmental area and nucleus accumbens of the rat brain. J Neurosci 16: 2605-2611. (Pubitemid 26124349)
74. White FJ, Wang RY (1984). Pharmacological characterization of dopamine autoreceptors in the rat ventral tegmental area: microiontophoretic studies. J Pharmacol Exp Ther 231: 275-280. (Pubitemid 15213833)
75. Wilson AA, McCormick P, Kapur S, Willeit M, Garcia A, Hussey D et al (2005). Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4,4a,5,6,10b- hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J Med Chem 48: 4153-4160. (Pubitemid 40800622)